Abstract: A method for recovering rare earth metals from zeolite-containing waste FCC catalysts comprises an acid leaching step to remove the rare earth metals from the catalyst to form a leachate containing dissolved rare earth metals and separating the rare earth metals from the leachate such as by precipitation.

Abstract: The present invention provides a new class of excited state intramolecular charge transfer (ESIPT) dye compounds based on mono or dihydroxy substituted 1,3-bisiminoisoindole motif and metal complexes containing such compounds as ligands. The present invention also provides OLEDs containing the compound and/or metal complex as the emissive material.

Abstract: Borohydride metallocene complex of lanthanide, preparation process, catalytic system incorporating borohydride metallocene complex, process for copolymerization of olefins employing catalytic system. The complex corresponds to one or other of formulae A and B: where, in A, two ligands Cp1, Cp2, each composed of a cyclopentadienyl group, are connected to the lanthanide Ln, such as Nd, and where, in B, a ligand molecule, composed of two cyclopentadienyl groups Cp1, Cp2 connected to one another via a bridge P of formula MR1R2, M is an element from group IVa, and R1 and R2, which are identical or different, represent an alkyl group comprising from 1 to 20 carbon atoms, is connected to the lanthanide Ln, L is alkali metal, N is molecule of a complexing solvent, x is integral or non-integral number?0, p is integer?than 1 and y is integer?0.

Abstract: The rare-earth complex of the present invention has high luminous efficiency, since it has a structure represented by the following general formula (I):

Abstract: The invention relates to a process for preparing a rare-earth organophosphate in the form of a fluid or not very viscous solution that can be used as is for the preparation of a “preformed” catalyst system intended, in particular, for the cis-1,4 stereospecific polymerization of conjugated dienes.

Abstract: The invention refers to new chemical compounds belonging to the known class of REE mixed ligand complexes, namely, to the compound of di-(nitrate)acetylacetonatobis (1,10-fenantrolin)lanthanide (III) of the general formula [Ln(NO3)2Acac(Phen)2]*H20, where Ln is TbxEr1-x, Acac is acetylacetonate-ion, Phen is 1,10-fenantrolin in the form suitable for application as a luminescent additive to ink for the hidden marking the valuables to provide protection against forgery. Such additive has three protective features suitable for automatic control independently of each other. The first protective feature is the ability to luminescence in green light under the impact of UV-radiation. The second protective feature is the ability to luminescence in green light under the impact of X-rays. The third protective feature is the Thermo-luminescence, which means the ability to accumulate for indefinite time span the energy of UV- and X-rays with subsequent green light emission at heating.

Abstract: Mixed metal phosphonates are generally provided. The mixed metal phosphonate can generally have the composition: AB(RPO3)3, where A is Mg2+, Ca2+, Sr2+, Ba2+, Pb2+, La3+, or combinations thereof; B is Ti4+, Zr4+, Al3?, or combinations thereof; and R is an organic group (e.g., aryl group, an alkyl group, an alkenyl group, etc.). The mixed metal phosphonate can be combined with a polymeric material to form a polymeric film. Methods of making the mixed metal phosphonate by combining and reacting a metal oxide and an organophosphonic acid are also provided.

Abstract: Preparation of semiconductor nanocrystals and their dispersions in solvents and other media is described. The nanocrystals described herein have small (1-10 nm) particle size with minimal aggregation and can be synthesized with high yield. The capping agents on the as-synthesized nanocrystals as well as nanocrystals which have undergone cap exchange reactions result in the formation of stable suspensions in polar and nonpolar solvents which may then result in the formation of high quality nanocomposite films.

Abstract: The present invention relates to a compound of formula (I). Provided is also a method of killing a cell that comprises administering the compound of formula (I). Provided is also a method of treating cancer or diabetes in a mammal that comprises administering the compound of formula I and respective pharmaceutical compositions thereof.

Abstract: A Ianthanide complex, method of forming and method of using the lanthanide complex as a near-infrared luminescent material are described. The complex includes at least one lanthanide ion and at least one polydentate ligand derived from a molecule having the general formula of Structure: Structure 2, where: E represents a heteroatom or heteroatom-containing group and R1R8 are independently selected from H, —OH, —NH2, —SO3H, —CO2H, halides, optionally substituted organic groups; and conjugated linking groups which link two of the polydentate ligands of Structure 2 together.

Abstract: There is provided a metal complex that is large in degree of a change in emission intensity, the change being caused by a change in molecular structure of a ligand through a photochromic reaction. The metal complex is arranged such that a diarylethene-based photochromic molecule coordinates to a metal ion via two groups directly bonded to respective reaction site carbons and that the groups are each independently a group selected from Formula Group (1) above.

Abstract: A process is provided that includes performing a high-temperature high-pressure hydrothermal treatment for a reaction liquid prepared as a mixture of an acylated inorganic fine particle precursor and an organic modifying agent that has a carboxyl group. Because the reaction liquid contains the acylated inorganic fine particle precursor in advance, the grain growth during the high-temperature high-pressure hydrothermal treatment can be suppressed. The process thus enables production of organic-modified inorganic fine particles of a size about the same as or even smaller than that before the high-temperature high-pressure hydrothermal treatment.

Abstract: There is provided a method for cleaving a target nucleic acid at a desired site using a metal ion or a metal ion complex as a catalyst for cleaving a nucleic acid (DNA, etc.), which has high site-selectivity, high reaction efficiency and low side-reactivity (non-specific reactivity), and is economical and convenient. The method for cleaving a target nucleic acid of the present invention comprises allowing a target nucleic acid to come into contact with a specific complex compound and a metal ion or a metal complex, or allowing a target nucleic acid to come into contact with a specific complex compound, to which a metal ion or a metal complex binds.

Abstract: [Object] The invention provides catalysts that are not corroded in acidic electrolytes or at high potential and have excellent durability and high oxygen reducing ability. [Solution] A catalyst of the invention includes a metal oxycarbonitride that contains titanium and at least one metal (hereinafter, also referred to as “metal M” or simply “M”) selected from silver, calcium, strontium, yttrium, ruthenium, lanthanum, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium and lutetium.

Abstract: Compounds of the formula: Wherein R is selected from the group consisting of H, NH2, and NHBoc; and R? is selected from the group consisting of H, CH2Ph and tBu, optionally de-protected. Such compounds may be conjugated with a suitable molecule able to interact with physiological systems; and their chelates with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203Pb, 67Ga, 68Ga, 72As, 111In, 113In, 90Y, 97Ru, 62Cu, 64Cu, 52Fe, 52mMn, 140La, 175Yb, 153Sm, 166Ho, 149Pm, 177Lu, 142Pr, 159Gd, 212Bi, 47Sc, 149Pm, 67Cu, 111Ag, 199Au, 161Tb, 51Cr, 167Tm, 141Ce, 168Yb, 88Y, 165Dy, 166Dy, 97Ru, 103Ru, 186Re, 188Re, 99mTc, 211Bi, 212Bi, 213Bi, 214Bi, 105Rh, 109Pd, 117mSn, 177Sn and 199Au, as well as the salts thereof with physiologically compatible bases or acids.

Abstract: Provided is a method for synthesizing a rare-earth oxo isopropoxide safely with a high yield, using a rare-earth metal, which is more inexpensive than anhydrous rare-earth chlorides, as a raw material. In a solvent containing 90% or more by weight of isopropyl alcohol, a rare-earth metal and isopropyl alcohol are caused to react with each other in the presence of a mercury compound catalyst, a solvent is added thereto or the solvent is partially replaced, and then in a solvent containing 25% or more by weight of an aromatic hydrocarbon solvent having 6 to 10 carbon atoms or a saturated hydrocarbon solvent having 5 to 12 carbon atoms, water is added to conduct partial hydrolysis reaction, thereby synthesizing a rare-earth oxoisopropoxide.

Abstract: The invention relates to novel electropolymerisable monomers which are to be polymerised in an aqueous solution and comprise: an electropolymerisable pattern selected from acetylene, pyrrols, thiophenes, indols, anilines, azines, p-phenylene vinylenes, p-phenylenes, pyrenes, furanes, selenophenes, pyrridazines, carbazoles, acrylates, methacrylates and the derivatives thereof, and a metalloporphyrine which is substituted by at least two ionised or ionizable entities in an aqueous solution. The invention also relates to a method for the polymerization of such monomers, to the electroactive probe that can be obtained by the polymerization of such monomers, and to a method for detecting a target ligand in a biological sample using one such electroactive probe.

Abstract: Methods and compositions for the deposition of ternary oxide films containing ruthenium and an alkali earth metal.

Abstract: The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.

Abstract: The present invention provides an article of manufacture formed from a substrate and a benzazoloporphyrazine bound to the substrate. The article may take a variety of different forms and may be for example an electrochromic display, a molecular capacitor, a battery, a solar cell, or a molecular memory device. Methods of making such articles, along with compounds, methods and intermediates useful for making such benzazoloporphyrazines, are also described.

Abstract: Processes are provided for producing transition metal amides. In methods according to this invention, at least a halogenated transition metal and an amine are combined in a solvent to produce an intermediate composition and an alkylated metal or a Grignard reagent is added to the intermediate composition to produce the transition metal amide.

Abstract: The present invention provides a fluorescent substance excellent in emission intensity and in emission efficiency. The substance can be excited by light at a longer wavelength than ever. The present invention also provides a luminous composition comprising the fluorescent substance and a light-emitting element using the substance. The fluorescent substance comprises a rare earth metal and a phosphine oxide ligand which coordinates to said rare earth metal and said ligand containing at least one siloxane bond in its structure. The fluorescent substance can be produced from a reaction between a compound having a siloxane bond and a rare earth complex coordinated by a phosphine oxide ligand. The luminous composition comprises the fluorescent substance.

Abstract: Mixed metal phosphonates are generally provided. The mixed metal phosphonate can generally have the composition: AB(RPO3)3, where A is Mg2+, Ca2+, Sr2+, Ba2+, Pb2+, La3+, Co2+, Mn2+, Fe2+, or combinations thereof; B is Ti4+, Zr4+, Al3+, or combinations thereof; and R is an organic group (e.g., aryl group, an alkyl group, an alkenyl group, etc.). The mixed metal phosphonate can be combined with a polymeric material to form a polymeric film. Methods of making the mixed metal phosphonate by combining and reacting a metal oxide and an organophosphonic acid are also provided.

Abstract: This invention relates to a diagnostic probe comprising a compound of formula (I): such as 3-[2-[4-(5-aminopentyl-3-amidocarboxypropanoyl)]aminophenyl]ethyl]-8-benzyl-7-[2-ethyl(2-hydroxyethyl)amino]ethyl-1-propylxanthine, with one or more label moieties attached thereto. The compounds of the present invention are useful as diagnostic probes, including probes for diagnostic assays and imaging. Accordingly, the invention provides A1 adenosine receptor antagonist compounds with radioactive or non-radioactive labels suitable for executing such assays and imaging measurements. Labeled compounds are useful to obtain quantitative measurements of the A1 adenosine receptor antagonist compounds. They may be employed as an imaging agent in diagnostic procedures such as MRI and PET as well as cell or receptor based assays.

Abstract: The invention provides modified oligonucleotides of formula (I), comprising at least one metal chelator which provides a powerful tool for study of the pharmacokinetics of siRNA and its correlation with in vivo activity. The chelated metals provide luminescent properties enable detection of the oligonucleotides through the use of time-resolved fluorescent quenching based on energy transfer from the metal ion to a nonfluorescent quencher which can be used as non-isotopic labels of oligonucleotides for diagnostics and evaluation of cellular uptake.

Abstract: The invention relates to stereoregular ROMP polymers, the monomers used to make them, and the processes used to convert the monomers to the polymers.

Abstract: Compositions for producing multi-chromic (“color”) magnetic resonance images (MRI). The compositions for use as MRI imaging agents include a magnetic resonance imaging tracer having a signal emitter, such as a 19F imaging tracer (19FIT), conjugated with a magnetic signal modulator, such as a paramagnetic functional group or a paramagnetic ion. The 19FIT and the signal modulator (M) are joined covalently by a chelator such as DOTA, forming a nanometer-sized fluorinated paramagnetic complex 19FIT-DOTA-M. Other signal emitters, such as 31P imaging tracer (31PIT), can also be modulated using this strategy (i.e., 31PIT-DOTA-M) to generate multi-chromic 31P MRI or MRS.

Abstract: This invention relates to organometallic compounds represented by the formula M(NR1R2)x wherein M is a metal or metalloid, R1 is the same or different and is a hydrocarbon group or a heteroatom-containing group, R2 is the same or different and is a hydrocarbon group or a heteroatom-containing group; R1 and R2 can be combined to form a substituted or unsubstituted, saturated or unsaturated cyclic group; R1 or R2 of one (NR1R2) group can be combined with R1 or R2 of another (NR1R2) group to form a substituted or unsubstituted, saturated or unsaturated cyclic group; x is equal to the oxidation state of M; and wherein said organometallic compound has (i) a steric bulk sufficient to maintain a monomeric structure and a coordination number equal to the oxidation state of M with respect to anionic ligands, and (ii) a molecular weight sufficient to possess a volatility suitable for vapor deposition; a process for producing the organometallic compounds, and a method for producing a film or coating from organometallic

Abstract: Rare earth metal precursors, for use in MOCVD techniques have a ligand of the general formula OCR1(R2)CH2X, wherein R1 is H or an alkyl group, R2 is an optionally substituted alkyl group and X is selected from OR and NR2, wherein R is an alkyl group or a substituted alkyl group. Methods of making such precursors and methods of depositing metal oxide layers from such precursors are also described.

Abstract: The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.

Abstract: A metalorganic complex composition comprising a metalorganic complex selected from the group consisting of: metalorganic complexes comprising one or more metal central atoms coordinated to one or more monodentate or multidentate organic ligands, and complexed with one or more complexing monodentate or multidentate ligands containing one or more atoms independently selected from the group consisting of atoms of the elements C, N, H, S, O and F; wherein when the number of metal atoms is one and concurrently the number of complexing monodentate or multidentate ligands is one, then the complexing monodentate or multidentate ligand of the metalorganic complex is selected from the group consisting of beta-ketoiminates, beta-diiminates, C2-C10 alkenyl, C2-C15 cycloalkenyl and C6-C10 aryl.

Abstract: Porphyrin compounds are provided. The compounds may further comprise a fused polycyclic aromatic hydrocarbon or a fused heterocyclic aromatic. Fused polycyclic aromatic hydrocarbon s and fused heterocyclic aromatics may extend and broaden absorption, and modify the solubility, crystallinity, and film-forming properties of the porphyrin compounds. Additionally, devices comprising porphyrin compounds are also provided. The porphyrin compounds may be used in a donor/acceptor configuration with compounds, such as C60.

Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.

Abstract: Metal complexes, catalyst compositions containing the metal complexes, and processes for making the metal complexes and the catalyst compositions are described for the manufacture of polymers from ethylenically unsaturated addition polymerizable monomers. The metal complexes have chemical structures corresponding to one of the following formulae: wherein MI and MII are metals; T is nitrogen or phosphorus; P is a carbon, nitrogen or phosphorus atom; groups R1, R2 and R3 may be linked to each other; Y is a divalent bridging group; X, X1, and X2 are anionic ligand groups with certain exceptions; D is a neutral Lewis base ligand; and s, o, k, i, ii, p, m, a, b, c, d, c, t, and y are numbers as further described in the claims.

Abstract: This invention relates to organometallic compounds represented by the formula (L1)xM(L2)y wherein M is a metal or metalloid, L1 and L2 are different and are each a hydrocarbon group or a heteroatom-containing group; x is a value of at least 1; y is a value of at least 1; x+y is equal to the oxidation state of M; and wherein (i) L1 has a steric bulk sufficiently large such that, due to steric hinderance, x cannot be a value equal to the oxidation state of M, (ii) L2 has a steric bulk sufficiently small such that, due to lack of steric hinderance, y can be a value equal to the oxidation state of M only in the event that x is not a value of at least 1, and (iii) L1 and L2 have a steric bulk sufficient to maintain a heteroleptic structure in which x+y is equal to the oxidation state of M; a process for producing the organometallic compounds, and a method for producing a film or coating from organometallic precursor compounds.

Abstract: This invention relates to organometallic compounds represented by the formula M(NR1R2)x wherein M is a metal or metalloid, R1 is the same or different and is a hydrocarbon group or a heteroatom-containing group, R2 is the same or different and is a hydrocarbon group or a heteroatom-containing group; R1 and R2 can be combined to form a substituted or unsubstituted, saturated or unsaturated cyclic group; R1 or R2 of one (NR1R2) group can be combined with R1 or R2 of another (NR1R2) group to form a substituted or unsubstituted, saturated or unsaturated cyclic group; x is equal to the oxidation state of M; and wherein said organometallic compound has (i) a steric bulk sufficient to maintain a monomeric structure and a coordination number equal to the oxidation state of M with respect to anionic ligands, and (ii) a molecular weight sufficient to possess a volatility suitable for vapor deposition; a process for producing the organometallic compounds, and a method for producing a film or coating from organometallic

Abstract: Endohedral metallofullerene compounds, which in water has a relaxivity of about 30 mM?1 S?1 to about 300 mM?1 S?1 and forms a dispersion in water with entities having an average hydrodynamic radius of less than about 20 nm.

Abstract: A plurality of metal-containing complexes of a polydentate beta-ketoiminate, one embodiment of which is represented by the structure are shown: wherein M is a metal such as calcium, strontium, barium, scandium, yttrium, lanthanum, titanium, zirconium, vanadium, tungsten, manganese, cobalt, iron, nickel, ruthenium, zinc, copper, palladium, platinum, iridium, rhenium, osmium; wherein R1 is selected from the group consisting of alkyl, fluoroalkyl, cycloaliphatic, and aryl, having from 1 to 10 carbon atoms; R2 can be from the group consisting of hydrogen, alkyl, alkoxy, cycloaliphatic, and aryl; R3 is linear or branched selected from the group consisting of alkylene, fluoroalkyl, cycloaliphatic, and aryl; R4 is an alkylene bridge; R5-6 are individually linear or branched selected from the group consisting of alkyl, fluoroalkyl, cycloaliphatic, aryl, and they can be connected to form a ring containing carbon, oxygen, or nitrogen atoms; n is an integer equal to the valence of the metal M.

Abstract: A coated article comprising a substrate having a plastic surface and adhered thereto an organometallic film in which the metal has f electron orbitals or is niobium is disclosed. Also disclosed are methods for applying organometallic films to substrates and the organometallic films themselves.

Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.

Abstract: A functionalized trimetallic nitride endohedral fullerene based material can be represented according to the formula: A3-nXnN@Cm (R)o, wherein: where A and X are one or a combination of the following metal atoms: Sc, Y, La, Ce, Pr, Nd, Gd, Tb, Dy, Ho, Er, Tm, Lu; (n=0-3); N is nitrogen; Cm is a fullerene and m=about 60-about 200; and R is an organic, inorganic, or organometallic species. Related compositions, devices and methods are also described.

Abstract: There is provided a method of producing a rare earth salt of a dialkyl phosphate or a rare earth salt of dioleyl phosphate of a high purity useful as a polymerization catalyst of a conjugated diene compound by directly reacting a rare earth oxide or a rare earth hydroxide with a dialkyl phosphate or dioleyl phosphate of a high purity. In the invention, the rare earth oxide or rare earth hydroxide is reacted with the dialkyl phosphate or dioleyl phosphate of a high purity in a non-polar solvent in the presence of at least one compound selected from a halogenated hydroacid, phosphorous acid and a rare earth halide made from the same element as in an objective product as a catalyst.

Abstract: The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.

Abstract: Compounds of general formula (I): with substituents as defined herein and their chelates with bi-trivalent ions of the metal elements of atomic numbers 20 to 31, 39, 42, 43, 44, 49, and 57 to 83, and radioisotopes chosen among 203Pb, 67Ga, 68Ga, 72As, 111In, 113In, 90Y, 97Ru, 62Cu, 64Cu, 52Fe, 52mMn, 140La, 175Yb, 153Sm, 166Ho, 149Pm, 177Lu, 142Pr, 159Gd, 212Bi, 47Sc, 149Pm, 67Cu, 111Ag, 199Au, 161Tb, 51Cr, 167Tm, 141Ce, 168Yb, 88Y, 165Dy, 166Dy, 97Ru, 103Ru, 186Re, 99mTc, 211Bi, 213Bi, 214Bi, 105Rh, 109Pd, 177mSn, 177Sn and 199Au, as well as the salts thereof with physiologically compatible bases or acids.

Abstract: The present invention has been created to provide a near infrared high emission rare-earth complex having an excellent light-emitting property in the near infrared region. The near infrared high emission rare-earth complex of the present invention is characterized in that its structure is expressed by the following general formula (1): where Ln(III) represents a trivalent rare-earth ion; n is an integer equal to or greater than three; Xs represent either the same member or different members selected from a hydrogen atom, a deuterium atom, halogen atoms, C1-C20 groups, hydroxyl groups, nitro groups, amino groups, sulfonyl groups, cyano groups, silyl groups, phosphonic groups, diazo groups and mercapto groups; and Z represents a bidentate ligand.

Abstract: The present application relates to compounds of formulae I and II: in which, X1, X2, R1, R2, R6, R7, R8, L1, L2, L3, T1, T2, Z1, Z2 are chosen from various possible groups or entities. For example, the compounds of formulae I and II are used as ligands for preparing complexes of various metals.

Abstract: A new class of heterocyclic metallocenes, a catalytic system containing them and a process for polymerizing addition polymerizable monomers using the catalytic system are disclosed; the heterocyclic metallocenes correspond to the formula (I): YjR?iZjjMeQkPl wherein Y is a coordinating group containing a six ? electron central radical directly coordinating Me, to which are associated one or more radicals containing at least one non-carbon atom selected from B, N, O, Al, Si, P, S, Ga, Ge, As, Se, In, Sn, Sb and Te; R? is a divalent bridge between the Y and Z groups; Z is a coordinating group, optionally being equal to Y; Me is a transition metal; Q is halogen or hydrocarbon substituents; P is a counterion; i is 0 or 1; j is 1-3; jj is 0-2; k is 1-3; and l is 0-2.

Abstract: A non-metallocene organometallic complex comprising a tridentate ligand and a metal bonded to a tridentate ligand, wherein two substituted aryl groups in the tridentate ligand are connected to a cyclic group at the ortho position via semi-rigid ring-ring linkages, and selected so to provide the resulting non-metallocene organometallic complex with a CS geometry, a C1 geometry, a C2 geometry or a C2v geometry. Method for performing olefin polymerization with a non-metallocene organometallic complex as a catalyst, related catalytic systems, tridentate ligand and method for providing a non-metallocene organometallic complex.

Abstract: The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.

Abstract: The invention relates to compounds, to the complexes they form with a lanthanide, and to the use of the complexes for fluorescence marking or NMR imaging. The complex consists of an Ln ion and a ligand R2—C(X—R1)(R3)—NR4R5. R1 is a functional group, X is a single bond or a hydrocarbon-based chain consisting of at least one alkylene or alkenylene group optionally comprising at least one hetero atom or an arylene. R2 is an anionic group A2 or a C1-C4 alkylene or alkenylene group bearing at least one such group A2 and optionally comprising at least one hetero atom. R3 is H or a C1-C5 alkylene or alkenylene group optionally containing at least one hetero atom, and optionally bearing at least one anionic group A3. R4 is a substituent with light-absorbing properties that forms chelate rings with Ln. R5 is a substituent that forms chelate rings with Ln.